February 08, 2012
   
Add to Google
New RA Therapy: Immune Reeducation vs. Immunosuppression
email a friend print


Smoking cigarettes may be worse for women's health than it is for men's. More >

Follow us on Twitter. Become a fan on Facebook. Receive updates via E-mail and SMS:







Would you like to ask our staff a question? >
Join the discussion and leave a comment on this article >

New RA Therapy: Immune Reeducation vs. Immunosuppression

Tom Gilbert
 
The immune system is our chief protector from disease. In people with rheumatoid arthritis, or RA, however, the immune system turns traitor and attacks the body instead.

If the immune system of RA patients could be altered, T cells might be less likely to cause chronic inflammation.

Though there is no cure for RA, its symptoms are usually treated with immunosuppressants, but these medicines can, themselves, produce dangerous side effects. Now, however, a promising new treatment may be able to reeducate the body's immune system to stop it from attacking healthy joint tissue.

Affecting an estimated 2.1 million Americans, RA causes chronic joint inflammation and destruction, disability and even death. While its precise cause is unknown, researchers believe that RA has to do with an immune system overreaction, in certain genetically susceptible individuals, to something in the environment.

The new treatment, called immune-modulation therapy, was developed by Salvatore Albani, M.D., Ph.D., UC San Diego professor of medicine and pediatrics, from his work on the immune system's T cells, which trigger inflammation to kill and clear infections from the body. Albani reasoned that if the immune system of RA patients could be altered, T cells might be less likely to cause chronic inflammation.

To prevent T cells from attacking the body, Albani sought to develop a vaccine therapy that could "reeducate" the diseased immune system in RA patients to prevent rampant inflammation. He focused on a protein called dnaJP1 that is used by T cells to help initiate the inflammation process. "We believed that if we could administer dnaJP1 as a vaccine to patients with early RA, it would affect the autoimmune inflammation," Albani said.

"In essence, we reeducated the immune system T cells in RA patients to be tolerant of the dnaJP1 amino acid sequence that would usually trigger inflammation," Albani said. This immune modulation, rather than immune suppression, prevented a T cell attack against the body's own tissue.

Asked for comment, TheDoctor's RA expert Dr. Peter Barland, Professor of Medicine Emeritus at the Albert Einstein College of Medicine in New York, said, "Oral immunotherapy as a potential treatment for RA is an idea with obvious potential. So far, however, the data is much too preliminary to judge its safety and effectiveness. While oral antigens have been shown to shift autoimmune excitation to immune tolerance, e.g., myelin basic protein in multiple sclerosis, their clinical trials have been very disappointing."

The new treatment is currently being studied in clinical trials at the UC San Diego School of Medicine and several other schools. These are expected to be completed by the end of 2004.
May 10, 2004






 
 
Add Comment
NOTE: We regret that we cannot answer personal medical questions.

Name


Comment

Characters remaining:



Readers Comments
No comments have been made







This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.





The Doctor Will See You Now   |   LEGAL RESTRICTIONS AND TERMS OF USE OF THIS SITE. USE OF THIS SITE IS YOUR AGREEMENT TO THESE TERMS.
Copyright 2012 interMDnet Corporation. All rights reserved.
About Us | Privacy Policy | Disclaimer | System Requirements